CA
NZ
UK
AU
IND
US
Evommune, Inc. (NYSE:EVMN) drew elevated trading interest in the September 2026 session even as shares closed little changed, down 0.19% at $10.54 at last closing. The near-flat session arrived at a sensitive moment for the company, which had guided investors to expect a pivotal …
Few biotechnology debutants have carried as much buzz into the back half of 2026 as Generate Biomedicines, Inc. The AI-driven protein-design company, trading onNasdaqunder the ticker GENB, has lined up an unusually dense run of September investor conferences, and shares closed up 2.14% at …
Apnimed, Inc. (NASDAQ:APMD) has been one of the most talked-about biopharma listings of the summer, arriving on theNasdaqin late July 2026 with a lead candidate aimed at one of medicine's largest undertreated markets: obstructive sleep apnea. After an eventful debut and a fresh set …
American Scientific Resources, Incorporated (OTC:ASFX) is one of the market's true ghost tickers, a onetime medical-device maker whose shares are quoted at essentially nothing and whose corporate paper trail went quiet more than a decade ago. Priced at a hundredth of a penny or …
Barely a month after its market debut, Attovia Therapeutics, Inc. (NASDAQ:ATTO) closed up 1.15% at $22.79 at last closing. The immunology-focused developer priced an upsized offering in early August 2026 and has traded well above its issue price since, offering investors a lesson in …
Few 2026 biotech debutants have commanded the attention that Avalyn Pharma Inc. (NASDAQ:AVLN) has drawn since its spring listing. Shares closed down 3.17% at $33.57 at last closing, a modest pullback that has prompted some holders to revisit the company's rich valuation even as …
Small-cap wellness names can move sharply on modest volume, but Bio Essence Corp (OTC:BIOE) held flat at $0.18 at last closing. The California-based supplement maker has spent 2026 trying to reposition itself, upgrading its market tier and floating anAcquisitionto push into digital health, and …
Fresh from a summer stock-market debut, BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) is still finding its footing as a public company, and shares closed down 3.02% at $20.86 at last closing. The oncology-focused biotech went public in August 2026 and quickly traded well above its offering …
Aktis Oncology, Inc (NASDAQ:AKTS) has slipped in a September 2026 session, nudging the targeted-radiopharmaceutical developer back into focus during a busy stretch for freshly listed oncology names. Shares closed down 2.67% at $23.30 at last closing, a pullback that is modest by biotech standards, …
Few 2026 healthcare debutants have captured investor imagination like Alamar Biosciences, Inc. (NASDAQ:ALMR). The proteomics company priced its initial public offering in April 2026 and has since become a closely followed name in the liquid-biopsy and precision-medicine arena. Shares closed up 0.43% at $27.89 …
Please wait processing your request...